Moderna Prices Upsized $2.6 Billion Offering of Convertible Senior Notes
Moderna Inc (NASDAQ:MRNA) has priced an upsized $2.6 billion offering of convertible senior notes due in 2032, following a private placement. The company initially announced plans for a $2 billion offering but increased the size to meet strong investor demand. The zero-coupon notes carry no interest and are expected to provide Moderna with significant capital that could be used for general corporate purposes or research and development activities. This move reflects confidence in the biotech firm’s long-term growth potential, particularly as it continues to develop vaccines and therapies beyond its flagship mRNA-based products. The offering is part of a broader trend among life sciences companies seeking to raise funds through convertible debt instruments amid favorable market conditions.
Tickers: $MRNA